

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SAREPTA THERAPEUTICS, INC.,

Petitioner

v.

GENZYME CORPORATION,

Patent Owner

---

**U.S. Patent No. 9,051,542**

“Compositions and Methods to Prevent AAV Vector Aggregation”

---

IPR2025-01194

**PETITIONER’S POWER OF ATTORNEY**


Pursuant to 37 C.F.R. 42.10(b), Petitioner Sarepta Therapeutics, Inc. (“Sarepta”) hereby appoints the following attorneys to transact all business in the United States Patent and Trademark Office for the *Inter Partes* Review of U.S. Patent No. 9,051,542.

Robert Wilson (Reg. No. 45,227) (Lead Counsel)  
Quinn Emanuel Urquhart & Sullivan, LLP  
295 Fifth Avenue, 9th Floor  
New York, New York 10016  
robertwilson@quinnemanuel.com  
Telephone (212) 849-7000

Anne Toker (Reg. No. 53,692) (Back-Up Counsel)  
James Glass (Reg. No. 46,729) (Back-Up Counsel)  
Quinn Emanuel Urquhart & Sullivan, LLP  
295 Fifth Avenue, 9th Floor  
New York, New York 10016  
annetoker@quinnemanuel.com  
jimglass@quinnemanuel.com  
Telephone (212) 849-7000

The individual signing below has the authority to execute this document on behalf of Sarepta.

Dated: June 26, 2025

Signed by:  
By:   
303777FE3E184B6...  
John X. Haberman  
Vice President, Chief Intellectual  
Property Officer  
SAREPTA THERAPEUTICS, INC.